Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men

Edward W. Hook; William M. McCormack; David Martin; Robert B. Jones; Karen Bean; Allan N. Maroli; H. Hunter Handsfield; John M. Douglas; Jonathan Zenilman; Peter Leone; Peter Rice

doi:10.1128/aac.41.8.1843

Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men

Edward W. Hook, William M. McCormack, David Martin, Robert B. Jones, Karen Bean, Allan N. Maroli, H. Hunter Handsfield, John M. Douglas, Jonathan Zenilman, Peter Leone, Peter Rice

School of Medicine

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

In a randomized open study, 351 male patients with uncomplicated gonorrhea were given single oral doses of grepafloxacin (400 mg) or cefixime (400 mg). In the 299 microbiologically evaluable patients, urethral infections were cured in 99% (147 of 149) of those receiving grepafloxacin and 97% (145 of 150) of those given cefixime. Eradication rates for both regimens were 100% in the 16% (47 of 299) of participants who were infected with penicillin-resistant Neisseria gonorrhoeae and 97% in the 21% (62 of 299) of participants infected with tetracycline-resistant strains. Grepafloxacin is a well-tolerated alternative to cefixime for treatment of uncomplicated gonorrhea in males.

Original language	English (US)
Pages (from-to)	1843-1845
Number of pages	3
Journal	Antimicrobial agents and chemotherapy
Volume	41
Issue number	8
DOIs	https://doi.org/10.1128/aac.41.8.1843
State	Published - Aug 1997

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/aac.41.8.1843

Cite this

@article{51888372828d414fa5d74ce37b929114,

title = "Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men",

abstract = "In a randomized open study, 351 male patients with uncomplicated gonorrhea were given single oral doses of grepafloxacin (400 mg) or cefixime (400 mg). In the 299 microbiologically evaluable patients, urethral infections were cured in 99% (147 of 149) of those receiving grepafloxacin and 97% (145 of 150) of those given cefixime. Eradication rates for both regimens were 100% in the 16% (47 of 299) of participants who were infected with penicillin-resistant Neisseria gonorrhoeae and 97% in the 21% (62 of 299) of participants infected with tetracycline-resistant strains. Grepafloxacin is a well-tolerated alternative to cefixime for treatment of uncomplicated gonorrhea in males.",

author = "Hook, {Edward W.} and McCormack, {William M.} and David Martin and Jones, {Robert B.} and Karen Bean and Maroli, {Allan N.} and Handsfield, {H. Hunter} and Douglas, {John M.} and Jonathan Zenilman and Peter Leone and Peter Rice",

year = "1997",

month = aug,

doi = "10.1128/aac.41.8.1843",

language = "English (US)",

volume = "41",

pages = "1843--1845",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "8",

}

TY - JOUR

T1 - Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men

AU - Hook, Edward W.

AU - McCormack, William M.

AU - Martin, David

AU - Jones, Robert B.

AU - Bean, Karen

AU - Maroli, Allan N.

AU - Handsfield, H. Hunter

AU - Douglas, John M.

AU - Zenilman, Jonathan

AU - Leone, Peter

AU - Rice, Peter

PY - 1997/8

Y1 - 1997/8

N2 - In a randomized open study, 351 male patients with uncomplicated gonorrhea were given single oral doses of grepafloxacin (400 mg) or cefixime (400 mg). In the 299 microbiologically evaluable patients, urethral infections were cured in 99% (147 of 149) of those receiving grepafloxacin and 97% (145 of 150) of those given cefixime. Eradication rates for both regimens were 100% in the 16% (47 of 299) of participants who were infected with penicillin-resistant Neisseria gonorrhoeae and 97% in the 21% (62 of 299) of participants infected with tetracycline-resistant strains. Grepafloxacin is a well-tolerated alternative to cefixime for treatment of uncomplicated gonorrhea in males.

AB - In a randomized open study, 351 male patients with uncomplicated gonorrhea were given single oral doses of grepafloxacin (400 mg) or cefixime (400 mg). In the 299 microbiologically evaluable patients, urethral infections were cured in 99% (147 of 149) of those receiving grepafloxacin and 97% (145 of 150) of those given cefixime. Eradication rates for both regimens were 100% in the 16% (47 of 299) of participants who were infected with penicillin-resistant Neisseria gonorrhoeae and 97% in the 21% (62 of 299) of participants infected with tetracycline-resistant strains. Grepafloxacin is a well-tolerated alternative to cefixime for treatment of uncomplicated gonorrhea in males.

UR - http://www.scopus.com/inward/record.url?scp=8544225736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8544225736&partnerID=8YFLogxK

U2 - 10.1128/aac.41.8.1843

DO - 10.1128/aac.41.8.1843

M3 - Article

C2 - 9257777

AN - SCOPUS:8544225736

SN - 0066-4804

VL - 41

SP - 1843

EP - 1845

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 8

ER -

Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this